Skip to main content

Top navigation

  • Important Safety Information
  • Prescribing Information
  • For HCPs »

Top Navigation - Secondary

  • Find an Infusion Center
  • Connect With an Alnylam Educator
  • Stay Informed

Facebook Icon YouTube Icon

Facebook Icon YouTube Icon

ONPATTRO® (patisiran) Logo
ONPATTRO® (patisiran) Logo

Main navigation

  • Disease
    Overview
  • How ONPATTRO
    May Help
    • About ONPATTRO
    • Possible Side Effects
  • Treatment With
    ONPATTRO
    • Treatment Process
    • Find an Infusion Center
  • Support &
    Resources
    • Alnylam Assist™
    • Connect With an Alnylam Educator
    • Resources
  • Connect With an Alnylam Educator
  • Stay Informed
  • Important Safety Information
  • Prescribing Information
  • For Healthcare Professionals

Facebook Icon YouTube Icon

Facebook Icon YouTube Icon

 

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about ONPATTRO® (patisiran)?

ONPATTRO can cause:

  • Infusion-related reactions

    ONPATTRO is given as a drip into a vein (called an "intravenous infusion"). Reactions to this infusion may happen during treatment with ONPATTRO. Before each infusion you will be given medicines that help to lower the chance of infusion-related reactions.

    Tell your doctor or nurse right away if you experience any of the following signs of an infusion-related reaction during treatment:

    • Reddening of the face or body (flushing), skin warm
    • Body aches or pain, including pain in the back, neck, or joints
    • Feeling sick (nausea)
    • Stomach pain
    • Feeling short of breath, cough, or other breathing problems
    • Headache
    • Chest discomfort or chest pain
    • Rash
    • Chills
    • Dizziness
    • Feeling tired (fatigue)
    • Rapid heart rate
    • Facial swelling

    If you have an infusion-related reaction, your doctor or nurse may slow down or stop your infusion, and you may need to take other medicines. When these reactions stop, or get better, your doctor or nurse may decide to start the infusion again.

  • Low Vitamin A levels

    Treatment with ONPATTRO lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking ONPATTRO, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of ONPATTRO?

The most common side effects of ONPATTRO are respiratory infections, such as colds, sinus infections, and nasal congestion, and infusion-related reactions. These are not all the possible side effects of ONPATTRO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is ONPATTRO?

ONPATTRO is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). ONPATTRO is used in adults only.

For additional information about ONPATTRO, please see the full Prescribing Information.

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about ONPATTRO® (patisiran)?

ONPATTRO can cause:

  • Infusion-related reactions

    ONPATTRO is given as a drip into a vein (called an "intravenous infusion"). Reactions to this infusion may happen during treatment with ONPATTRO. Before each infusion you will be given medicines that help to lower the chance of infusion-related reactions.

    Tell your doctor or nurse right away if you experience any of the following signs of an infusion-related reaction during treatment:

    • Reddening of the face or body (flushing), skin warm
    • Body aches or pain, including pain in the back, neck, or joints
    • Feeling sick (nausea)
    • Stomach pain
    • Feeling short of breath, cough, or other breathing problems
    • Headache
    • Chest discomfort or chest pain
    • Rash
    • Chills
    • Dizziness
    • Feeling tired (fatigue)
    • Rapid heart rate
    • Facial swelling

    If you have an infusion-related reaction, your doctor or nurse may slow down or stop your infusion, and you may need to take other medicines. When these reactions stop, or get better, your doctor or nurse may decide to start the infusion again.

  • Low Vitamin A levels

    Treatment with ONPATTRO lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking ONPATTRO, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of ONPATTRO?

The most common side effects of ONPATTRO are respiratory infections, such as colds, sinus infections, and nasal congestion, and infusion-related reactions. These are not all the possible side effects of ONPATTRO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is ONPATTRO?

ONPATTRO is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). ONPATTRO is used in adults only.

For additional information about ONPATTRO, please see the full Prescribing Information.

Questions? Call 1-833-256-2748

Footer menu

  • Privacy Policy
  • Legal Notice
  • Contact Us
  • Site Map

Alnylam Pharmaceuticals Logo

ONPATTRO and Alnylam Assist are registered trademarks of Alnylam Pharmaceuticals, Inc.
© 2022 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US audiences. TTR02-USA-00027-092018-V7

You are now leaving ONPATTRO.com.

The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on
sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed

You are now leaving ONPATTRO.com.

You are now being directed to another Alnylam website.

Proceed

You are now leaving ONPATTRO.com.

The information contained in this section of the site is intended for US healthcare professionals only.

click CONTINUE if you are a healthcare professional

Continue

The safety and effectiveness of ONPATTRO® (patisiran) were evaluated against placebo in a study of 225 patients with hATTR amyloidosis with polyneuropathy. This means some patients received a placebo that did not contain medication.

Alert icon

This email address is already in use.

Please press Cancel to enter another email, or press Update to receive an email that will allow you to update your preferences.

Cancel Update
Verification sent icon

Email sent!

A link has been sent to your email address.

OK